103418-06-0

Basic information

• Product Name: 4-(4-METHYLPHENYL)-1H-PYRROLE-3-CARBONITRILE
• Synonyms: 4-(4-METHYLPHENYL)-1H-PYRROLE-3-CARBONITRILE
• CAS NO: 103418-06-0
• Molecular Formula: C₁₂H₁₀N₂
• Molecular Weight: 182.2212
• Mol File: 103418-06-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-METHYLPHENYL)-1H-PYRROLE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHYLPHENYL)-1H-PYRROLE-3-CARBONITRILE(103418-06-0)
• EPA Substance Registry System: 4-(4-METHYLPHENYL)-1H-PYRROLE-3-CARBONITRILE(103418-06-0)

Safety Data

• Hazardous Substances Data: 103418-06-0(Hazardous Substances Data)

Upstream product

• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 64636-81-3 N-(cyanomethyl)pyridinium bromide 
• 104-87-0 4-methyl-benzaldehyde 

Downstream Products

• 142015-51-8 1-methyl-4-p-tolyl-1H-pyrrole-3-carbonitrile 

Relevant articles and documents

Method of preparing 4,5-disubstituted 1,2,3-triazole with pyridinium salt

The invention relates to a method of synthesizing a 4,5-disubstituted 1,2,3-triazole compound. The method comprises the following step of by taking pyridine, halohydrocarbon, sulfonic ester, aldehydeand sodium azide as raw materials, and performing room-temperature reaction with a one-pot method. The synthetic method does not need a metal-containing catalyst, has the advantages of high yield of synthetic products, mild reaction condition, good functional group compatibility and the like, is simple in operation step, mild in reaction condition and wide in application range of a substrate, hasinnovativeness and a potential practical value and is suitable for industrial production.

NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4) ; Y2 represents N or C(R5) ; R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxygroup or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, ahalogenatometc.; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.